CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

The control group will not receive hydroxychloroquineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1086 Hydroxychloroquine Wiki 0.10

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D018450 Disease Progression NIH 0.26
D007239 Infection NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death

This is a multi-center, randomized controlled, superiority, open label trial. The objective of this trial is to evaluate the efficacy of HCQ in patients with newly diagnosed COVID-19 who have mild to moderate disease or at risk for complications. We aim to demonstrate decrease in progression to severe pneumonia and hospital related complications among patients who are treated with HCQ compared to patients who are not.

NCT04323631 COVID-19 Drug: Hydroxychloroquine Other: The control group will not receive hydroxychloroquine
MeSH:Infection Disease Progression

Primary Outcomes

Description: Number patients developing severe infection or death

Measure: Number patients developing severe infection or death

Time: within 28 days

No related HPO nodes (Using clinical trials)